NCT02052297 - A Validation and Dosimetry Study of GSK2634673F PET Ligand | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2014

Primary Completion Date

April 21, 2016

Study Completion Date

April 21, 2016

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

OTHER

GSK2634673F

GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.

Trial Locations (2)

NW10 7EW

GSK Investigational Site, London

W12 0NN

GSK Investigational Site, London